BioCentury
ARTICLE | Company News

Tesaro, Merck deal

June 29, 2015 7:00 AM UTC

The companies partnered to evaluate Tesaro’s niraparib ( MK-4827) in combination with Merck’s melanoma drug Keytruda pembrolizumab in a Phase I/II trial to treat triple-negative breast cancer or ovar...